Canadian Cancer Trials Group Bulletins

Trial Management Group

Permanent Trial Closures

Two trials have recently been permanently closed:

BL.8 (EORTC 30994): Randomized Phase III Trial Comparing Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 and/or N+M0 Transitional Cell Carcinoma (TCC) of the Bladder.


MA.21: A Phase III Adjuvant Trial of Sequenced EC + Filgrastim + Epoetin Alfa Followed by Paclitaxel Versus Sequenced AC Followed by Paclitaxel Versus CEF as Therapy for Premenopausal Women and Early Postmenopausal Women Who Have Had Potentially Curative Surgery for Node Positive or High Risk Node Negative Breast Cancer.

Any documentation submitted to Canadian Cancer Trials Group Central Office for these trials will be not be accepted and will be returned to sites. Health Canada, the NCI US, intergroup collaborators and industry partners have been notified of these final trial closures.

Centres should notify their REB of any outstanding ethics documents and of the final completion of these trials.

For complete information, please visit the "Permanent Trial Closure" area of the members area here: ,as well notification is posted on each trial page.